Alastair Kilgour

GeoSpock enables data fusion for the connected world. Engineered for dynamically fusing any-scale connected device, smart city, or IoT data, GeoSpock unlocks next-generation use cases, whilst also reducing the complexity, cost, and operating latency when compared to competing database solutions. GeoSpock DB is a next-generation database built for high-performance analytics across any scale of data. Our unique Cambridge-built technology enables you to carry out dynamic data fusion and rapidly execute complex queries using SQL. The logical upgrade to your existing analytics technology – GeoSpock DB is built to power your data-driven future.

Aqdot is a Cambridge (UK)-based supramolecular chemistry company with a focus and expertise in developing, licensing and selling novel proprietary products. The Aqdot Solutions part of the business works in partnership with customers to understand their challenges and develop solutions utilising the unique AqBit technology. This has the team working in areas from air filtering in transportation to delivery of therapeutics for cancer. In parallel the Aqdot Products part of the company has recently launched its own brands AqStar™ M1 and Oderase to date. Again, working with partners either on a distribution basis, or offering the opportunity to “white label” or develop a market specific formulation.

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic

GeoSpock enables data fusion for the connected world. Engineered for dynamically fusing any-scale connected device, smart city, or IoT data, GeoSpock unlocks next-generation use cases, whilst also reducing the complexity, cost, and operating latency when compared to competing database solutions. GeoSpock DB is a next-generation database built for high-performance analytics across any scale of data. Our unique Cambridge-built technology enables you to carry out dynamic data fusion and rapidly execute complex queries using SQL. The logical upgrade to your existing analytics technology – GeoSpock DB is built to power your data-driven future.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Aqdot is a Cambridge (UK)-based supramolecular chemistry company with a focus and expertise in developing, licensing and selling novel proprietary products. The Aqdot Solutions part of the business works in partnership with customers to understand their challenges and develop solutions utilising the unique AqBit technology. This has the team working in areas from air filtering in transportation to delivery of therapeutics for cancer. In parallel the Aqdot Products part of the company has recently launched its own brands AqStar™ M1 and Oderase to date. Again, working with partners either on a distribution basis, or offering the opportunity to “white label” or develop a market specific formulation.

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic

Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. As well as its flagship, evergreen Opportunities EIS Fund and Knowledge Intensive EIS Funds, Parkwalk also manages award-winning enterprise and innovation funds for the Universities of Cambridge, Oxford, Bristol and Imperial College. Parkwalk invests in businesses creating solutions to real-world challenges, with IP-protected innovations, across a range of sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech and big data.